Clinical Trial Update: Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)

View source ↗

Summary

Clinical trial update assessing quality of life in treatment-naïve Hepatitis C genotype 1 patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Exviera (dasabuvir)
• Viekirax (ombitasvir/paritaprevir/ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Virus (HCV) | Status: COMPLETED | Results posted: 2019-10-23